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INTRODUCTION  
Valganciclovir HCl (VGC), chemically L-Valine, 2[(2-
amino-1,6-dihydro-6-oxo-9H-purin-9-yl)methoxy]-3-
hydroxypropyl ester, monohydrochloride. (Figure 1) is a 
white to off-white crystalline powder with a molecular 
formula of C14H22N6O5·HCl and a molecular weight of 
390.83 It is an antiviral medication used to treat 
cytomegalovirus infections. As the L-valyl ester of 
ganciclovir, it is actually a prodrug for ganciclovir. After 
oral administration, it is rapidly converted to ganciclovir 
by intestinal and hepatic esterases. The mechanism of 
action of Valganciclovir is that it is a prodrug of 
ganciclovir that exists as a mixture of two diastereomers. 
After administration, these diastereomers are rapidly 
converted to ganciclovir by hepatic and intestinal 
esterases. In cytomegalovirus infected cells, ganciclovir is 
initially phosphorylated to the monophosphate form by 
viral protein kinase, then it is further phosphorylated via 
cellular kinases to produce the triphosphate form. This 
triphosphate form is slowly. Very few methods are 
reported in the literature including liquid chromatographic 
methods2-4, spectrophotometric techniques5 and 
LC/MS/MS6-8 methods for the determination of 
Valganciclovir in tablet dosage forms and in biological 
fluids. Suresh Kumar et al., have studied the Impurity 
profile and related substances9 of Valganciclovir and 
Stefanidis et al., studied the reactivity10 of Valganciclovir 
in aqueous solution. In the present work the authors have 
proposed a simple, rapid, robust, precise and accurate 
reverse phase liquid chromatographic method for the 
determination of Valganciclovir in tablet dosage forms.  
MATERIALS AND METHODS 
Chemicals and Reagents  
Valganciclovir standard (purity ≥ 99.98%) was obtained 
from Roche, India.  Methanol (HPLC grade), sodium 
hydroxide and hydrochloric acid, Glacial acetic acid and 
hydrogen peroxide were purchased from Merck (India).  
Valganciclovir is available as tablets with brand name 
VALCYT® as tablets (Label claim: 450 mg). All chemicals 
were of analytical grade and used as received.   
 
Figure 1: Chemical structure of Valganciclovir (VGC) 
Instrumentation and Chromatographic Conditions 
Chromatographic separation was achieved by using a 
Shimadzu Model CBM-20A/20 Alite HPLC system, 
equipped with SPD M20A prominence photodiode array 
detector (250 mm × 4.6 mm, 5 µm particle size) 
maintained at 25 ºC. Isocratic elution was performed using 
a mixture of methanol, water and glacial acetic acid 
(45:55:0.1,v/v) with flow rate 0.8 mL/min. 20 µL of each 
solutions were injected into the HPLC system.  
Preparation of Valganciclovir Stock Solution 
Valganciclovir stock solution (1000 μg/mL) was prepared 
by accurately weighing 25 mg of Valganciclovir in a 25 
mL amber volumetric flask and making up to volume with 
mobile phase. Working solutions for HPLC injections 
were prepared from the stock solution mobile phase. 
Solutions were filtered through a 0.45 μm membrane filter 
prior to injection. 
Assay of marketed formulations 
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Twenty tablets from each brand (VALCYT®) were 
procured, weighed and crushed to a fine powder. Powder 
equivalent to 25 mg Valganciclovir was accurately 
weighed into a 25 ml volumetric flask and made up to 
volume with mobile phase. The contents of the volumetric 
flask were sonicated for 30 min to enable complete 
dissolution of Valganciclovir. The solution was filtered 
and the filtrate was diluted with mobile phase. 20 μL of 
these solutions were injected into the system and the peak 
area was recorded from the respective chromatogram.  
Forced Degradation Studies/Specificity  
Forced degradation studies were performed to evaluate the 
stability indicating properties and specificity of the method 
11. All solutions for use in stress studies were prepared at 
an initial concentration of 1 mg/mL of Valganciclovir and 
refluxed for 30 min at 80 ºC. All samples were then diluted 
in mobile phase to give a final concentration of 100 μg/mL 
and filtered before injection.  
Acidic and Alkaline Degradation  
Acid decomposition was carried out in 0.1 M HCl at a 
concentration of 1.0 mg/mL Valganciclovir and after 
refluxation for 30 min at 80 ºC the stressed sample was 
cooled, neutralized and diluted with mobile phase to give a 
final concentration of 100 μg/mL and filtered before 
injection. Similarly stress studies in alkaline conditions 
were conducted using a concentration of 1.0 mg/mL in 0.1 
M NaOH and refluxed for 30 min at 100 ºC. After cooling 
the solution was neutralized and diluted with mobile phase 
to give a final concentration of 100 μg/mL and filtered 
before injection.  
Oxidative Degradation  
Solutions for oxidative stress studies were prepared using 
3% H2O2 at a concentration of 1 mg/mL of Valganciclovir 
and after refluxation for 30 min at 100 ºC on the 
thermostat the sample solution was cooled and diluted with 
the mobile phase to give a final concentration of 100 
μg/mL and filtered before injection.  
Thermal Degradation 
For thermal stress testing, the drug solution (1 mg/mL) 
was heated in thermostat at 100 ºC for 30 min, cooled and 
diluted with the mobile phase to give a final concentration 
of 100 μg/mL and filtered before injection.  
Method Validation  
The method was validated for the following parameters: 
system suitability, linearity, limit of quantitation (LOQ), 
limit of detection (LOD), precision, accuracy, selectivity 
and robustness12. 
Linearity  
Linearity test solutions for the assay method were prepared 
from a stock solution at different concentration levels of 
the analyte (1.0-200 µg/mL). 20 µL of each solution was 
injected in to the HPLC system and the peak area of the 
chromatogram obtained was noted.  
Precision  
The intra-day precision of the assay method was evaluated 
by carrying out 9 independent assays of a test sample of 
Valganciclovir at three concentration levels (10, 20 and 50 
µg/mL) (n=3) against a qualified reference standard. The 
%RSD of three obtained assay values at three different 
concentration levels was calculated. The interday precision 
study was performed on three different days i.e. day 1, day 
2 and day 3 at three different concentration levels (10, 20 
and 50 µg/mL) and each value is the average of three 
determinations (n=3). The % RSD of three obtained assay 
values on three different days was calculated.  
Accuracy  
The accuracy of the assay method was evaluated in 
triplicate at three concentration levels (80, 100 and 120%), 
and the percentage recoveries were calculated. Standard 
addition and recovery experiments were conducted to 
determine the accuracy of the method for the 
quantification of Valganciclovir in the drug product. The 
study was carried out in triplicate at 18, 20 and 22 µg/mL. 
The percentage recovery in each case was calculated.  
Sensitivity/Limit of quantification (LOQ) and limit of 
detection (LOD)  
The limit of quantification (LOQ) and limit of detection 
(LOD) were based on the standard deviation of the 
response and the slope of the constructed calibration curve 
(n=3), as described in International Conference on 
Harmonization guidelines Q2 (R1) 12. Sensitivity of the 
method was established with respect to limit of detection 
(LOD) and LOQ for Valganciclovir. LOD and LOQ were 
established by slope method as mentioned below. LOD 
and LOQ were experimentally verified by injecting six 
replicate injections of each impurity at the concentration 
obtained from the above formula. 
LOD  = 
3.3 × standard deviation of y-intercept 
Slope of the calibration curve 
LOQ  = 
10 × standard deviation of y-intercept 
Slope of the calibration curve 
Robustness  
The robustness of the assay method was established by 
introducing small changes in the HPLC conditions which 
included wavelength (252 and 256 nm), percentage of 
methanol in the mobile phase (53 and 57) and flow rate 
(0.7 and 0.9 mL/min). Robustness of the method was 
studied using six replicates at a concentration level of 20 
µg/mL of Valganciclovir.  
RESULTS AND DISCUSSION  
A reversed-phase liquid chromatographic technique was 
developed to quantitate Valganciclovir in pharmaceutical 
dosage forms. No stability indicating liquid 
chromatographic method was reported earlier in the 
literature. A detailed comparative study of the previously 
published methods with the present method was given in 
Table 1. 
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Table 1 Comparison of the performance characteristics of the present method with the published methods 
S. 
No. 
Method /Reagent 
λ 
(nm) 
Linearity 
(g/mL) 
Remarks Ref 
1. 
(HPLC ) 
Acetonitrile:methanol:KH2PO4 (pH 5.0) 
(40:20:40,v/v) 
 
255 
 
10-3000 
 
human serum 
 
2 
2. 
(HPLC ) 
Acetonitrile: Potassium dihydrogen phosphate 
(pH 4.0) (60:40,v/v) 
254 0.01-60 Low linearity range 3 
3 
(HPLC ) 
n-Hexane: ethanol: isopropyl alcohol: tri-fluoro 
acetic acid (98: 1.5: 0.5: 0.1,v/v/v/v) 
215 
 
– 
 
Chiral purity 
 
 
4 
4 
(Spectrophotometry) 
Methanol 
254 
5-39 
 
Very narrow linearity range 5 
5 LC/MS - - Human plasma 6 
6 LC/MS/MS - - 
Plasma and its active 
metabolites 
7 
7 LC/MS/MS - - 
Plasma and its active 
metabolites 
8 
8 
(HPLC) 
Methanol: trifluoro acetic acid (Gradient mode) 
- - 
Impurity profile and related 
substances 
 
9 
9 
(HPLC) 
Methanol:  water:glacial acetic acid 
(55:44:0.1,v/v) 
254 
 
1.00-200 
Stability indicating method 
Wide linearity range 
(PDA detector) 
 
Present 
work 
 
A reversed-phase chromatographic technique was 
developed for the determination of Valganciclovir in 
tablets. Satisfactory resolution was achieved with use of a 
mixture of methanol, water and glacial acetic acid 
(55:45:0.1,v/v) with UV detection at 254 nm (Figure 2). 
C8 and C18 columns were first evaluated as stationary 
phase for the separation of Valganciclovir but C18 column 
was adopted for the analysis as it has provided a better 
separation of the analytes.  
HPLC Method Development and Optimization  
Initially the stressed samples were analyzed using a mobile 
phase consisting of water: acetonitrile (70:30, v/v) at a 
flow rate of 1.0 mL/min. Under these conditions, the 
resolution and peak symmetry were not satisfactory, so the 
mobile phase was changed to methanol: water (40:60,v/v) 
with a flow rate of 1.0 mL/min under which peak tailing 
was observed.  
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Figure 2: Typical Chromatogram of Valganciclovir (100 μg/mL) 
Finally the mobile phase containing methanol: water: 
glacial acetic acid (45:55: 0.1,v/v) was chosen as the best 
chromatographic response for the entire study where a 
sharp peak was observed around 2.5 mins.  
Method Validation  
Linearity  
The calibration curve for Valganciclovir was linear over 
the concentration range of 1.00–200 μg/mL. The data for 
the peak area of the drug in corresponds to the 
concentration was treated by linear regression analysis 
(Table 2) and the regression equation for the calibration 
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curve (Figure 3) was found to be y = 50968 x + 86374 
with correlation coefficient of 0.999.  
Limit of Detection and Limit of Quantification 
The LOQ and LOD were found to be 0.8641 μg/mL and 
0.2813 μg/mL respectively.  
 
Table 2: Linearity of Valganciclovir 
Conc. (μg/mL) *Mean peak area ± SD RSD (%) 
1 124567 ± 361.24 0.29 
5 417982 ±1379.34 0.33 
10 517992 ±2538.16 0.49 
20 1195971 ±7893.41 0.66 
50 2645833 ± 14022.31 0.53 
100 5177187 ± 19673.31 0.38 
150 7778901 ± 63786.99 0.52 
200 10237618 ± 38902.95 0.38 
 
 
Figure 3: Calibration Curve of Valganciclovir 
Precision  
The inter-day precision was calculated by assaying three 
samples of each at three different concentration levels (10, 
20 and 50 µg/mL) on three different days. The % RSD 
range was obtained as 0.28-0.61 and 0.35-0.89 for intra-
day and inter-day precision studies respectively (Table 3).  
Accuracy  
The method accuracy was proven by the recovery test. A 
known amount of Valganciclovir standard (10 μg/mL) was 
added to aliquots of samples solutions and then diluted to 
yield total concentrations as 18, 20 and 22 μg/mL as 
described in Table 3. The assay was repeated over 3 
consecutive days. The resultant % RSD was 0.29-0.92 
(<2.0 %) with a recovery 98.78-98.82 %.
 
Table 3: Precision and accuracy study of Valganciclovir 
Conc. 
(µg/mL) 
Intra-day precision Inter-day precision 
*Mean peak area  ± SD (% RSD) *Mean peak area ± SD (% RSD) 
10 517987 ± 1450.36 (0.28) 517889 ± 1812.6115 (0.35) 
20 1195891 ± 5859.86 (0.49) 1196981 ± 6703.09 (0.56) 
50 2644929 ±16134.06 (0.61) 2645032 ± 23540.78 (0.89) 
Accuracy 
Conc. 
(µg/mL) 
*Mean peak area ± SD (% RSD) *Drug found (µg/mL) % Recovery* 
18 698456.00 ± 20255.24 (0.29) 17.78 98.79 
20 1088191.00 ± 7073.24 (0.65) 19.96 99.82 
22 1745889.00 ± 16062.17 (0.92) 21.73 98.78 
*Mean of three replicates 
Robustness  
The robustness of an analytical procedure refers to its 
ability to remain unaffected by small and deliberate 
variations in method parameters and provides an indication 
of its reliability for routine analysis 12. The robustness of 
the method was evaluated by assaying the same sample 
under different analytical conditions deliberately changing 
from the original condition. The detection wavelength was 
set at 252 and 256 nm (± 2 nm), the ratio of percentage of 
water: methanol  in the mobile phase was applied as 53:47 
and 57:43 (± 2 %, v/v), the flow rate was set at 0.7 and 0.9 
mL/min (± 0.1 mL/min). The results obtained from assay 
of the test solutions were not affected by varying the 
conditions and were in accordance with the results for 
original conditions. The % RSD value of assay determined 
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for the same sample under original conditions and 
robustness conditions was less than 2.0% indicating that 
the developed method was robust (Table 4). 
 
Table 4: Robustness study of Valganciclovir 
Parameter Condition 
*Mean peak 
area 
*Mean ± SD  
(% RSD) 
% Assay* 
Flow rate (mL/min) 
0.7 519835 
517805.33 ± 3003.27 
(0.58) 99.98 
0.8 517992 
0.9 515589 
Detection wavelength (nm) 
252 510881 
512087.33 ± 3943.07 
(0.77) 99.80 
254 517992 
256 507389 
Mobile phase composition 
(Water: Methanol) (v/v) 
53:47 510831 
516255.00 ± 4956.04 
(0.96) 98.94 
55:45 517992 
57:43 519942 
*Mean of three replicates 
Analysis of Commercial Formulations (Tablets) 
The proposed method was applied to the determination of 
Valganciclovir tablets and VALCYT® and the result of 
these assays yielded 99.81 % respectively  with RSD < 2.0 
%. The result of the assay (Table 5) indicates that the 
method is selective for the assay of Valganciclovir without 
interference from the excipients used in these tablets. The 
typical chromatograms for Valganciclovir obtained from 
the extracted marketed formulations were shown in 
Figure 4.
 
Table 5: Analysis of Valganciclovir commercial formulation (Tablets) 
Sample 
No. 
Formulation Labeled claim (mg) 
*Amount found   
(mg) 
*Recovery (%) 
1 VALCYT® 450 388.41 99.81 
*Mean of three replicates 
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Figure 4: Typical Chromatogram of Valganciclovir (100 μg/mL) VALCYT® (450 mg) 
Selectivity/Specificity  
The specificity of the developed method was determined 
by injecting sample solutions (100 μg/mL) which were 
prepared by forcibly degrading under such stress 
conditions as heat, light, oxidative agent, acid and base 
under the proposed chromatographic conditions. The 
stability indicating capability of the method was 
established from the separation of Valganciclovir peak 
from the degraded samples derived from the software. The 
degradation of Valganciclovir was found to be very similar 
for both the tablets and standard.  
Solution Stability and Mobile Phase Stability   
The %RSD of the assay of Valganciclovir from the 
solution stability and mobile phase stability experiments 
was within 2%. The results of the solution and mobile 
phase stability experiments confirm that the sample 
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solutions and mobile phase used during the assays were 
stable up to 48 h at room temperature and up to 3 months 
at 4ºC.  
Forced Degradation Studies  
Valganciclovir standard and tablet powder was found to be 
quite stable under dry heat conditions. Typical 
chromatograms obtained following the assay of stressed 
samples are shown in Figure 5 (A-E). 
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Figure 5: Typical Chromatograms of Valganciclovir (100 μg/mL)) on Acidic [A], Alkaline [B], Oxidative [C] and 
Thermal [D] Degradations 
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A very slight decomposition was seen on exposure of 
Valganciclovir drug solution to acidic (3.23), alkaline 
(3.21) and oxidation (1.25). During the oxidative 
degradation a major degradants were observed at 3.482 
mins without interfering the elution of drug peak. 
Valganciclovir has undergone thermal degradation (1.11) 
very slightly and Table 6 summarises the data of 
degradation studies.   
System Suitability  
The system suitability test was performed to ensure that 
the complete testing system was suitable for the intended 
application. The parameters measured were peak area, 
retention time, tailing factor, capacity factor and 
theoretical plates. In all measurements the peak area varied 
less than 2.0%, the average retention time was 5.5 ± 0.05 
minutes. The capacity factor was more than 2, theoretical 
plates were more than 2000 and tailing factor was less than 
1.5 for the Valganciclovir peak (Table 6). 
 
Table 6: Forced degradation studies of Valganciclovir 
Stress conditions 
*Mean peak 
area 
% Drug 
recovered 
% Drug 
decomposed 
Theoretical 
plates 
Tailing factor 
Standard Drug 5195753 100 - 4261.187 1.012 
Acidic degradation 5081089 96.77 3.23 4169.378 1.011 
Alkaline degradation 5075503 96.79 3.21 4087.112 1.013 
Oxidative degradation 4657716 98.75 1.25 4066.286 1.004 
Thermal degradation 5177187 98.89 1.11 4031.448 1.118 
*Mean of three replicates 
CONCLUSION 
The proposed stability-indicating HPLC method was 
validated as per ICH guidelines and can be applied for the 
determination of Valganciclovir in pharmaceutical dosage 
forms. The method was found to be accurate, precise, 
robust and specific as the drug peak did not interfere with 
the extra peaks aroused during the forced degradation 
studies. At the same time the chromatographic elution step 
is undertaken in a short time (< 3 min). No interference 
from any components of pharmaceutical dosage form can 
be successfully applied to perform accelerated stability 
studies of Valganciclovir formulations.  
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